Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
Open Access
- 28 April 2021
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (16), 1738-1750
- https://doi.org/10.3748/wjg.v27.i16.1738
Abstract
The coronavirus disease 2019 (COVID-19) outbreak has drawn the scientific community's attention to pre-existing metabolic conditions that could aggravate the infection, causing extended viral shedding, prolonged hospitalization, and high death rates. Metabolic dysfunction-associated fatty liver disease (MAFLD) emerges as a surrogate for COVID-19 severity due to the constellation of metabolic alterations it entails. This review outlines the impact MAFLD exerts on COVID-19 severity in obese subjects, besides the possible mechanistic links to the poor outcomes. The data collected showed that MAFLD patients had poorer COVID-19 outcomes than non-MAFLD obese subjects. MAFLD is generally accompanied by impaired glycemic control and systemic arterial hypertension, both of which can decompensate during the COVID-19 clinical course. Also, MAFLD subjects had higher plasma inflammatory marker concentrations than non-MAFLD subjects, which might be related to an intensified cytokine storm syndrome frequently associated with the need for mechanical ventilation and death. In conclusion, MAFLD represents a higher risk than obesity for COVID-19 severity, resulting in poor outcomes and even progression to non-alcoholic steatohepatitis. Hepatologists should include MAFLD subjects in the high-risk group, intensify preventive measurements, and prioritize their vaccination.Keywords
This publication has 84 references indexed in Scilit:
- Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated SignalingCell Metabolism, 2012
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatmentMetabolism, 2011
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistanceNature Medicine, 2011
- The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism, 2010
- Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic SteatohepatitisClinics in Liver Disease, 2009
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- An obesity-associated gut microbiome with increased capacity for energy harvestNature, 2006
- Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2Gut, 2005
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004